- Home
- TENB vs RARE Comparison
TENB vs RARE Comparison
Compare TENB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | RARE |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | 1371 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TENB | RARE |
|---|---|---|
| Price | $37.63 | $25.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 20 |
| Target Price | $31.69 | ★ $59.10 |
| AVG Volume (30 Days) | ★ 3.0M | 2.1M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.23 | ★ 7.31 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $999,405,000.00 | $673,000,000.00 |
| Revenue This Year | $9.37 | $13.12 |
| Revenue Next Year | $7.04 | $37.80 |
| P/E Ratio | $752.40 | ★ N/A |
| Revenue Growth | 11.04 | ★ 20.13 |
| 52 Week Low | $15.73 | $18.29 |
| 52 Week High | $43.67 | $39.89 |
Technical Indicators
Market Signals| Indicator | TENB | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 54.84 | 45.44 |
| Support Level | $25.99 | $24.22 |
| Resistance Level | $40.19 | $28.13 |
| Average True Range (ATR) | 1.95 | 1.10 |
| MACD | -0.05 | 0.13 |
| Stochastic Oscillator | 60.16 | 28.33 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.